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Summary Trichosporon (T.) asahii can cause superficial skin infections 
and can be an opportunistic pathogen that produces potentially fatal 
systemic infections in immunocompromised hosts. We report a case of 
lower limb infection due to T. asahii in an immunocompetent patient who 
displayed no evidence of underlying disease. There is a strong possibility 
that our patient had been colonized at the infection site as part of the 
normal skin flora. After one-month bed rest due to an accidental fall and 
fracture of the right shoulder blade, a 61-year-old woman experienced 
severe edema and redness in the right lower limb and received topical 
treatment with iodine solution and antibiotics without improvement. She 
presented at our Outpatient Clinic with cellulitis and lymphedema. Sam-
ples collected from the affected areas revealed T. asahii and the patient 
was referred to a hospital for infectious diseases for appropriate therapy. 
The patient was treated with wound dressings until she was admitted to 
our intensive care unit when her general condition abruptly deteriorated. 
Despite in vitro susceptibility results, therapy with liposomal amphoteri-
cin and voriconazole could not change the fatal outcome. Nowadays, 
physicians must suspect this emerging difficult-to-treat fungal pathogen 
and treatment must start promptly in these infections.
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IntrODuCtIOn
Trichosporon asahii is a basidiomycetous, nonder-
matophytic fungus widely distributed in soil, vegeta-
tion, and water and may be part of the normal human 
skin and respiratory tract flora (1). Trichosporon (T.) 
asahii has been recognized as the cause of superficial 
skin infections, such as white piedra. It can also be an 
opportunistic pathogen that produces potentially 
fatal systemic infections in immunocompromised 
hosts, particularly those with underlying hematolog-
ic malignancy (2). Rarely, T. asahii has been isolated 
from patients who displayed no evidence of underly-
ing disease (3-5).
CaSE rEPOrt
We report a case of lower limb infection due to 
T. asahii in an immunocompetent patient who dis-
played no evidence of underlying disease but devel-
oped an ultimately lethal T. asahii systemic infection. 
There is a strong possibility that our patient had been 
colonized at the infection site as part of the normal 
skin flora. After one-month bed rest due to an acci-
dental fall and fracture of the right shoulder blade, a 
61-year-old woman experienced severe edema with 
an overlying erythematous patch in the right lower 
limb. The patient used iodine solution to the affected 
area for about two weeks. Furthermore, the skin le-
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sions were mistaken by the family doctor as erysipe-
las and antibiotics were prescribed without improve-
ment. She presented at our Outpatient Clinic with fe-
ver, cellulitis and lymphedema. She was in otherwise 
good health. No one in her family or friends had simi-
lar lesions and she had no pets in her house. Physical 
examination revealed no pathology of the venous or 
arterial system and there was no regional or gener-
alized lymphadenopathy or hepatosplenomegaly. 
Routine blood cell count and serum electrolytes were 
within the normal limits.
Direct microscopic examination with 15% potas-
sium hydroxide (KOH) solution of the material col-
lected from the affected area showed pseudohyphae. 
Culture on Sabouraud dextrose agar medium (Oxoid 
Ltd., Basingstoke, UK) supplemented with chlor-
amphenicol (Sigma, St. Louis, MO, USA) and cyclo-
heximide (Sigma, St. Louis, MO, USA) incubated for 2 
weeks at 25 °C yielded white to deep-cream colored, 
wrinkled colonies (Fig. 1). Microscopic examination 
after staining with lactophenol cotton blue showed 
true hyphae, pseudohyphae, a few blastoconidia, 
and rectangular arthroconidia typical of Trichospo-
ron species. The identification of T. asahii was con-
firmed by using the Vitek 2 automated biochemical 
testing system (BioMerieux, Marcy l’Etoile, France). 
These colonies were identified as T. asahii using the 
API 20C AUX assimilation assay (BioMerieux, Inc., 
Lyon, France). MICs were as follows: for amphotericin 
B, 16 μg/mL; fluconazole, 1 μg/mL; itraconazole, 0.25 
μg/mL; and voriconazole, 0.06 μg/mL. To confirm our 
findings, second samples from the affected limb were 
collected with the same results. She was referred to 
another hospital for appropriate antifungal therapy. 
For a period of one month, the patient received local 
treatment with wound dressings and topical cortico-
steroids but the skin lesions did not respond to this 
therapy, and instead spread to the whole limb (Fig. 
2). Subsequently she developed high fever with he-
modynamic deterioration and was admitted to our 
Intensive Care Unit. Despite in vitro susceptibility 
results, intravenous therapy with liposomal ampho-
tericin B (5 mg/kg daily) and voriconazole (6 mg/kg 
twice daily) could not change the outcome and the 
patient expired after the first 24 hours of therapy due 
to multiorgan failure and septic shock. Since T. asahii 
can be a life-threatening pathogen, it is imperative 
nowadays that physicians suspect this emerging diffi-
cult-to-treat fungal pathogen and start the treatment 
promptly in these infections.
DISCuSSIOn
Trichosporon asahii has been recognized as the 
main Trichosporon species that causes systemic in-
fection in humans (6). Recently, after examining skin 
samples from 380 healthy individuals using a nested 
PCR assay, it was found that this opportunistic yeast 
pathogen is part of the cutaneous fungal microbiota 
in humans and this may be one of the routes through 
which trichosporonosis is acquired (7).
Most cases of superficial Trichosporon infections 
have involved immunocompromised, neutropenic 
patients with hematologic malignancies, usually 
mimicking an eczema (8). Nevertheless, there are few 
reports involving immunocompetent hosts present-
ing with superficial cutaneous infections (9-11).
Predisposing risk factors associated with infec-
tions caused by T. asahii include treatment with im-
munosuppressive drugs, presence of implanted 
Figure 1. Trichosporon asahii culture on Sabouraud 
dextrose agar.
Figure 2. Lower limb infection by Trichosporon asa-
hii.
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prosthetic devices, transplantation, acquired immu-
nodeficiency syndrome, extensive burns (12) and 
prolonged use of antibiotics (13). However, a case of 
fatal septic shock by T. asahii has been reported in a 
patient who did not have cancer or neutropenia (3), 
while a case of disseminated trichosporonosis by T. 
asahii in a healthy adult woman with no underlying 
disease has been reported in China (9). 
Disseminated infections due to T. asahii are diffi-
cult to resolve, while the antifungal agents approved 
for the treatment of Trichosporon infections are lim-
ited. It has been demonstrated that monotherapy of 
disseminated trichosporonosis is usually unsuccess-
ful (3,6). A previous study of the in vitro antifungal 
susceptibility of Trichosporon species showed that 
voriconazole, posaconazole, and ravuconazole were 
more active than amphotericin B or fluconazole (14). 
On the other hand, combination regimens with syn-
ergistic antifungals could provide additional options 
for treating these infections. Interestingly, in a recent 
study, the combined antifungal activities of the echi-
nocandin caspofungin and the polyene amphoteri-
cin B against clinical isolates of T. asahii were more 
effective than monotherapy, suggesting that com-
bined antifungal therapy may be a potential strategy 
for treating disseminated trichosporonosis (15). The 
automated commercial system VITEK 2 used for the 
identification and susceptibility testing of our T. asa-
hii isolate was found comparable to the Clinical and 
Laboratory Standards Institute (CLSI M27-A3) refer-
ence broth microdilution method (16).
Cutaneous infection by T. asahii in immunocom-
petent hosts, as observed in our patient, is not usual. 
Our patient had suffered from gradually expanding 
skin lesions to which various treatments, including 
antibiotics, were ineffective. It can be easily specu-
lated that, at the initial stage, the patient may have 
been affected by a superficial form of trichosporono-
sis that, due to the delay in diagnosis and treatment, 
may have disseminated. In the immunocompromised 
body, dissemination may occur, but this is usually un-
expected in the immunocompetent host. In our pa-
tient, it is possible that the prolonged use of topical 
corticosteroids, due to misdiagnosis of the cutaneous 
lesions, induced a localized immune deficit that fa-
cilitated the subsequent dissemination of the infec-
tion. Infection with this unusual pathogen should be 
considered in those immunocompetent patients pre-
senting with skin lesions that continue to persist after 
prolonged treatment with topical steroids.
COnCLuSIOn
We have described a fatal case of lower limb cuta-
neous infection by T. asahii in an immunocompetent 
woman. In conclusion, it is important to acknowledge 
the poor prognosis that can be associated with infec-
tions due to T. asahii, which has the potential for inva-
sive infection in the immunocompromised patient as 
well as in the immunocompetent host.
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